Full Press Release Details
FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome.
LXRX
FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
Key Takeaway: FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome